Dr. Efuni has extensive experiences in academia and clinical practices in immunology/allergy, oncology, cardiology, endocrinology etc.  Dr. Efuni has managed clinical studies (Phases I-IV) in advanced solid tumors and hematological malignancies, chronic inflammatory, allergic disorders and neurology.  He has a track record of submissions/marketing approvals with the FDA and EMA including mogamulizumab (POTELIGEO) for CTCL/Cezary and istradefylline (NOURIANZ) for Parkinson’s disease (2019). Dr. Efuni received President Award (2018) with Kyowa Kirin and was speaker and clinical investigator for NovoNordisk, Sanofi, Ely Lilly.